FYB203
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for FYB203, covering 2025-11-13 to 2025-11-13. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration [Phase 3]